# US 2017/0362277 A1 · Cyclosporine analogue mixtures and their use as immunomodulating agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362277 A1
- Document ID: US20170362277A1
- Status: Published application
- Kind: A1
- Application number: 15/676,851
- Filed: 2017-08-14
- Published: 2017-12-21
- Earliest claimed: 2001-10-19
- Assignees: Aurinia Pharmaceuticals Inc.
- Applicants: Aurinia Pharmaceuticals Inc.
- Inventors: Selvaraj A. Naicker; Randall W. Yatscoff; Robert T. Foster
- Web page: https://patentgrep.com/patent/US20170362277A1

## CPC

- C07K 7/645: {Cyclosporins; Related peptides}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 38/13: Cyclosporins
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10S 530/806: Antigenic peptides or proteins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises from about 70 to about 80 percent by weight of the E-isomer and from about 20 to about 30 percent by weight of the Z-isomer, based on the total weight of the mixture.

## Claims

### Claim 1

A composition comprising an isomeric mixture of cyclosporine analogues modified at the 1-amino acid residue with a 1,3-diene substituent, wherein the isomeric mixture comprises from about 70% to about 80% of the E-isomer and from about 20% to about 30% of the Z-isomer, wherein the isomers are the E- and Z-isomers as specified below:

### Claim 2 (depends on 1)

A pharmaceutical composition comprising an isomeric cyclosporine analogue mixture according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, which comprises a gelatin capsule containing the isomeric analogue mixture, a liquid solution containing a surfactant, ethanol, a lipophilic and/or an amphiphilic solvent.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, which comprises a liquid solution containing a surfactant, ethanol, a lipophilic and/or an amphiphilic solvent.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, which comprises d-alpha Tocopheryl polyethylene glycol 1000 succinate, medium chain triglyceride oil, Tween 40, and ethanol.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, which is in unit dosage form.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, which contains from about 5 mg to about 500 mg of isomeric mixture.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, which contains about 50 mg isomeric mixture.

### Claim 9 (depends on 4)

The pharmaceutical composition of claim 4, wherein the solution contains about 50 mg/mL isomeric mixture.

### Claim 10 (depends on 3)

The pharmaceutical composition of claim 3, which is adapted for oral administration.

### Claim 11 (depends on 1)

A method of producing immunosuppression, the method comprising administering to a patient in need thereof a therapeutically effective amount of an isomeric cyclosporine analogue mixture according to claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein said immunosuppression is to treat or alleviate organ tissue transplant rejection.

### Claim 13 (depends on 12)

The method of claim 12 wherein said organ or transplant rejection is selected from the group consisting of: heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, bowel, and corneal transplants; T-cell mediated rejection; graft-versus-host disease; graft-versus-host disease following bone marrow transplantation; chronic rejection of a transplanted organ; graft vessel disease; xenograft rejection; acute, hyperacute and chronic rejection of an organ occurring when the organ donor is of a different species from the recipient; rejection mediated by B-cells; and antibody-mediated rejection.

### Claim 14 (depends on 11)

The method of claim 11, wherein said immunosuppression is to treat or alleviate an autoimmune disease or condition or an inflammatory disease or condition.

### Claim 15 (depends on 14)

The method of claim 14 wherein said disease or condition is selected from the group consisting of: arthritis, rheumatoid arthritis, arthritis chronica progrediente, arthritis deformans, other rheumatic diseases, hematological disorders, hemolytic anemia, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, (autoimmune) inflammatory bowel disease, ulcerative colitis, Crohn's disease, endocrine ophthalmopathy, Graves' disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca, vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, idiopathic nephrotic syndrome, minimal change nephropathy, juvenile dermatomyositis, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, epidermolysis bullosa acquisita, other inflammatory or allergic conditions of the skin, inflammatory conditions of the lungs and airways, asthma, allergies, and pneumoconiosis.

### Claim 16 (depends on 2)

A method of producing immunosuppression, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 2.

### Claim 17 (depends on 16)

The method of claim 16, wherein said immunosuppression is to treat or alleviate organ tissue transplant rejection.

### Claim 18 (depends on 17)

The method of claim 17, wherein said organ or transplant rejection is selected from the group consisting of: heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, bowel, and corneal transplants; T-cell mediated rejection; graft-versus-host disease; graft-versus-host disease following bone marrow transplantation; chronic rejection of a transplanted organ; graft vessel disease; xenograft rejection; acute, hyperacute and chronic rejection of an organ occurring when the organ donor is of a different species from the recipient; rejection mediated by B-cells; and antibody-mediated rejection.

### Claim 19 (depends on 17)

The method of claim 17, wherein said immunosuppression is to treat or alleviate an autoimmune disease or condition or an inflammatory disease or condition.

### Claim 20 (depends on 19)

The method of claim 19 wherein said disease or condition is selected from the group consisting of: arthritis, rheumatoid arthritis, arthritis chronica progrediente, arthritis deformans, other rheumatic diseases, hematological disorders, hemolytic anemia, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, (autoimmune) inflammatory bowel disease, ulcerative colitis, Crohn's disease, endocrine ophthalmopathy, Graves' disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca, vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, idiopathic nephrotic syndrome, minimal change nephropathy, juvenile dermatomyositis, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, epidermolysis bullosa acquisita, other inflammatory or allergic conditions of the skin, inflammatory conditions of the lungs and airways, asthma, allergies, and pneumoconiosis.

### Claim 21 (depends on 11)

The method of claim 11, wherein the isomeric cyclosporine analogue mixture has reduced toxicity relative to Cyclosporine A.

### Claim 22 (depends on 16)

The method of claim 16, wherein the mixture composition has increased efficacy relative to Cyclosporine A.

### Claim 23 (depends on 11)

The method of claim 11 wherein the isomeric cyclosporine analogue mixture is administered in an amount of about 5 to about 500 mg.

### Claim 24 (depends on 16)

The method of claim 16 wherein the pharmaceutical composition administered comprises an amount of isomeric cyclosporine analogue mixture of about 5 to about 500 mg.

### Claim 25 (depends on 21)

The method of claim 21 wherein the composition comprises the isomeric cyclosporine analogue mixture in an amount of about 5 to about 500 mg.
